Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00003686|
Recruitment Status : Terminated (Terminated due to poor accrual.)
First Posted : August 17, 2004
Last Update Posted : June 3, 2013
RATIONALE: Pilocarpine may help to relieve dry mouth in patients receiving opioids for cancer therapy. It is not yet known whether pilocarpine is more effective than no further treatment for this condition.
PURPOSE: Randomized phase III trial to determine the effectiveness of pilocarpine in treating patients who have dry mouth caused by opioids.
|Condition or disease||Intervention/treatment||Phase|
|Oral Complications Quality of Life||Drug: pilocarpine hydrochloride Drug: Placebo||Phase 3|
OBJECTIVES: I. Evaluate the effectiveness of daily oral pilocarpine versus placebo in relieving dry mouth due to the ongoing use of an opioid for cancer related pain at 2 weeks by comparing proportion of patients with at least one response during the 2 week period, time of first response, and duration of first response. II. Evaluate the adverse effects of pilocarpine in these patients. III. Evaluate whether constipation, sedation, poor appetite, and nausea are ameliorated by pilocarpine in these patients. IV. Evaluate the effect of pilocarpine on quality of life of this patient group. V. Determine the timing and duration of the effect of pilocarpine in this patient population.
OUTLINE: This is a randomized, double-blind, multicenter study. Patients receive either oral pilocarpine four times daily (arm I) or oral placebo four times daily (arm II) for 4 weeks. At the end of the 4 weeks, all patients are given the option to receive oral pilocarpine. Quality of life is assessed 2 days prior to randomization, after 2 weeks of treatment, and after 4 weeks of treatment.
PROJECTED ACCRUAL: There will be 60 patients accrued into this study within 18 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Primary Purpose:||Supportive Care|
|Official Title:||A Double Blind Phase III Study of Oral Pilocarpine for Opioid-Induced Dry Mouth|
|Study Start Date :||August 1998|
|Actual Primary Completion Date :||October 1999|
|Actual Study Completion Date :||November 1999|
|Active Comparator: Pilocarpine||
Drug: pilocarpine hydrochloride
Pilocarpine 5 mg po qid x 4 weeks
|Placebo Comparator: Placebo||
Placebo 5 mg po qid x 4 weeks
- Efficacy [ Time Frame: 10 years ]To evaluate, using a 100 mm VAS, the effectiveness of oral pilocarpine 5 mg qid in relieving dry mouth due to the ongoing use of an opioid for cancer related pain at 2 weeks (day 15). This will include comparing the proportion of at least one response during the 2 week period, time to first response and duration of first response.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003686
|Canada, British Columbia|
|BC Cancer Agency|
|Vancouver, British Columbia, Canada, V5Z 4E6|
|Humber River Regional Hospital|
|Weston, Ontario, Canada, M9N 1N8|
|Study Chair:||David Warr, MD||Princess Margaret Hospital, Canada|